EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Fluorinated perhexiline derivative attenuates vascular proliferation in pulmonary arterial hypertension smooth muscle cells

Kayleigh Griffiths, Roger J Grand, Ian Horan, Michelangelo Certo, Ross C Keeler, Claudio Mauro, Chih-Chung Tseng, Iain Greig, Nicholas W Morrell, Matteo Zanda, Michael P Frenneaux, Melanie Madhani

Vascular Pharmacology · 2024-09 · 156 · 107399

DOI: 10.1016/j.vph.2024.107399 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vascular Pharmacology, 2024-09. Verfasst von Kayleigh Griffiths und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK. Hauptthemen laut MEDLINE: Cell Proliferation, Pulmonary Artery, Myocytes, Smooth Muscle, Muscle, Smooth, Vascular. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation, Medical Research Council, University of Birmingham.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Increased proliferation and reduced apoptosis of pulmonary artery smooth muscle cells (PASMCs) is recognised as a universal hallmark of pulmonary arterial hypertension (PAH), in part related to the association with reduced pyruvate dehydrogenase (PDH) activity, resulting in decreased oxidative phosphorylation of glucose and increased aerobic glycolysis (Warburg effect). Perhexiline is a well-recognised carnitine palmitoyltransferase-1 (CPT1) inhibitor used in cardiac diseases, which reciprocally increases PDH activity, but is associated with variable pharmacokinetics related to polymorphic variation of the cytochrome P450-2D6 (CYP2D6) enzyme, resulting in the risk of neuro and hepatotoxicity in 'slow metabolisers' unless blood levels are monitored and dose adjusted. We have previously reported that a novel perhexiline fluorinated derivative (FPER-1) has the same therapeutic profile as perhexiline but is not metabolised by CYP2D6, resulting in more predictable pharmacokinetics than the parent drug. We sought to investigate the effects of perhexiline and FPER-1 on PDH flux in PASMCs from patients with PAH. We first confirmed that PAH PASMCs exhibited increased cell proliferation, enhanced phosphorylation of AKTSer473, ERK 1/2Thr202/Tyr204 and PDH-E1αSer293, indicating a Warburg effect when compared to healthy PASMCs. Pre-treatment with perhexiline or FPER-1 significantly attenuated PAH PASMC proliferation in a concentration-dependent manner and suppressed the activation of the AKTSer473 but had no effect on the ERK pathway. Perhexiline and FPER-1 markedly activated PDH (seen as dephosphorylation of PDH-E1αSer293), reduced glycolysis, and upregulated mitochondrial respiration in these PAH PASMCs as detected by Seahorse analysis. However, both perhexiline and FPER-1 did not induce apoptosis as measured by caspase 3/7 activity. We show for the first time that both perhexiline and FPER-1 may represent therapeutic agents for reducing cell proliferation in human PAH PASMCs, by reversing Warburg physiology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell ProliferationPulmonary ArteryMyocytes, Smooth MuscleMuscle, Smooth, VascularPerhexilineHumansCells, CulturedMalePhosphorylationFemalePulmonary Arterial HypertensionMiddle AgedSignal TransductionAntihypertensive AgentsAdultApoptosisCase-Control Studies

Stichwörter der Autor:innen

PerhexilinePulmonary arterial hypertensionPulmonary artery smooth muscle cellsPyruvate dehydrogenase

Substanzen

PerhexilineAntihypertensive Agents

Autor:innen und Institutionen

  • Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.
  • Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
  • Department for Medicine, University of Cambridge, Cambridge, UK.
  • Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.
  • Kosterlitz Centre for Therapeutics, University of Aberdeen, Aberdeen, UK.
  • The Institute of Chemical Sciences and Technologies, Milan, Italy.

Förderung

  • British Heart Foundation
  • Medical Research Council
  • University of Birmingham

Zitieren

APA

Griffiths, K., Grand, R. J., Horan, I., Certo, M., Keeler, R. C., Mauro, C., Tseng, C. C., Greig, I., Morrell, N. W., Zanda, M., Frenneaux, M. P., & Madhani, M. (2024). Fluorinated perhexiline derivative attenuates vascular proliferation in pulmonary arterial hypertension smooth muscle cells. Vascular Pharmacology, 156, 107399. https://doi.org/10.1016/j.vph.2024.107399

Vancouver

Griffiths K, Grand RJ, Horan I, Certo M, Keeler RC, Mauro C, et al. Fluorinated perhexiline derivative attenuates vascular proliferation in pulmonary arterial hypertension smooth muscle cells. Vascular Pharmacology. 2024;156:107399. doi:10.1016/j.vph.2024.107399

BibTeX
@article{Griffiths2024,
  author = {Griffiths, Kayleigh and Grand, Roger J and Horan, Ian and Certo, Michelangelo and Keeler, Ross C and Mauro, Claudio and Tseng, Chih-Chung and Greig, Iain and Morrell, Nicholas W and Zanda, Matteo and Frenneaux, Michael P and Madhani, Melanie},
  title = {Fluorinated perhexiline derivative attenuates vascular proliferation in pulmonary arterial hypertension smooth muscle cells},
  journal = {Vascular Pharmacology},
  year = {2024},
  volume = {156},
  pages = {107399},
  doi = {10.1016/j.vph.2024.107399}
}
Kostenlos starten →